New pill aims to curb heavy drinking: phase 2 trial results expected

NCT ID NCT06545916

Completed Disease control Sponsor: Knoa Pharma LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether the drug sunobinop (V117957) can reduce heavy drinking in adults with moderate to severe alcohol use disorder who want treatment. 209 participants took either sunobinop or a placebo daily for several weeks. The study measured changes in heavy drinking days and total drinks consumed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sunobinop (V117957)
What this could lead to: If successful, this could lead to a new medication that helps people with alcohol use disorder drink less heavily.
What could go wrong: This is a phase 2 trial, so it is still early. The drug may not work better than a placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Alcohol Drinking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER

Contacts and locations

Locations

Belmont Medical Office

Brooklyn, New York, 11212, United States
Bio Terra Med SRL

Bucharest, 010701, Romania
Cabinet Medical Individual Dr. Andreea Popa

Bucharest, 050802, Romania
Cebis Usa, Llc

Houston, Texas, 77074, United States
Inquest Clinical Research

Baytown, Texas, 77521, United States
Ohio Clinical Trials

Columbus, Ohio, 43212, United States
Spitalul Universitar De Urgenta Militar Central "Dr. Carol Davila"

Bucharest, 010825, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.